株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の消化器疾患治療薬市場:タイプ、投与経路、用途、地域別(2018年〜2023年)

Global Gastrointestinal Therapeutics Market - Segmented by Type, Dosage Form, Application and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 704952
出版日 ページ情報 英文 107 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=113.28円で換算しております。
Back to Top
世界の消化器疾患治療薬市場:タイプ、投与経路、用途、地域別(2018年〜2023年) Global Gastrointestinal Therapeutics Market - Segmented by Type, Dosage Form, Application and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年08月01日 ページ情報: 英文 107 Pages
概要

世界の消化器疾患治療薬市場は、2018年から2023年の調査期間を通じて5.8%のCAGRで推移することが予測されています。

当レポートでは、世界の消化器疾患治療薬市場を調査し、市場の概要、タイプ・投与経路・治療領域・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 市場のダイナミクス

  • 成長要因
    • ライフスタイルの変化による消化器疾患および癌の増加
    • 消化器疾患の手術件数の増加
    • 製薬企業による生物学的製剤およびバイオシミラーへの投資増加
  • 阻害要因
    • 消化器疾患に付随する社会経済的負担の増大
    • 特許満了を迎えた医薬品の増加
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • タイプ別
    • 先発医薬品
    • 後発医薬品(ジェネリック医薬品)
  • 投与経路別
    • 経口投与
    • 非経口投与
    • その他
  • 用途別
    • 潰瘍性大腸炎
    • 過敏性腸症候群
    • クローン病
    • セリアック病
    • 胃腸炎
    • 胃癌
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Abbott
  • Allergan PLC
  • アステラス製薬
  • AstraZeneca
  • Bayer AG
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Salix Pharmaceuticals
  • 武田薬品工業

第10章 市場の将来展望

目次
Product Code: 62814

Gastrointestinal Therapeutics Market Overview

The gastrointestinal therapeutics market is expected to register a growth rate of about 5.8% over the forecast period, 2018 to 2023. The gastrointestinal (GI) complaints are common among infants, children, and adults, which results from the reflux of stomach contents into the esophagus. The therapeutic management of gastrointestinal diseases and symptoms is majorly through pharmaceutical interventions, whose market is driven by lifestyle changes leading to GI diseases and increasing R&D investments in biologics and biosimilars. As per the geographical analysis, Asia-Pacific has several emerging countries with increasing privatization which is anticipated to provide lucrative opportunities for global companies in this market, over the forecast period.

Gastrointestinal Therapeutics Market is Primarily Driven by Rapid Lifestyle Changes

For a large number of gastrointestinal disorders as well as related cancer lesions, the lifestyle changes and choices play a major role. In Asia, as per a 2015 study reported in Gastroenterology and Hepatology, the cancers related to GI system are most common in Asia Pacific region, particularly due to high alcohol and tobacco use among all age groups. In developed markets as well, a significantly large population is highly troubled with the GI diseases such as in the US, morbid obesity and lifestyle factors high affects a large population of the country. In Europe, United European Gastroenterology (UEG) recently welcomed an MEP Digestive Health Group in the European Parliament, their third annual digestive health month campaign to raise awareness regarding a range of chronic digestive diseases across Europe. Thus, over the forecast period, the lifestyle changes would be a significant factor to drive the gastrointestinal therapeutics market, globally.

Other driving factors include rising surgical treatments and hospitalizations due to GI diseases and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars.

Increasing Socio-Economic Burden Associated with GI diseases Hinders the Growth of Gastrointestinal Therapeutics Market

The increasing acute GI diseases impose a great a burden socially and economically in low and middle-income countries. The distribution of gastrointestinal symptoms varies across social class and affects largely the population of low and middle-income countries. For example, the peptic ulcer disease is associated with low socioeconomic status. There are several studies reported across low and middle incomes countries where the low social class in the society has been linked to excess mortality from gastrointestinal diseases. Other factors such as physiological, behavioral, psychosocial, and socio-environmental risk factors, also restrict the populations from reporting the diseases early which reflects low awareness as well as an economic burden, restring the growth of the gastrointestinal therapeutics market.

Rising Economic Growth and Privatization in Medical Industry of Asia-Pacific Region Attracts High Growth Possibilities for Gastrointestinal Therapeutics Market

The Asian countries have shown the similar trend of growth in recent years as compared to western developed markets particularly owing to increasing economic growth along with privatization, competitive site experience, technological expertise, infrastructure, and scale to manage large-scale clinical trials across India, China, Japan, South Korea and others. The stomach related diseases have shown similar growth characteristics (incidence and prevalence) to western countries and thus the data of clinical trials are routinely accepted as part of US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory authorities. The unmet medical need and potential market opportunity have accelerated the partnerships with Asian pharmaceutical companies for development and commercial potential in the growth of the pharmaceutical business.

Key Developments in the Gastrointestinal Therapeutics Market

Jul 2018: HiFiBiO Therapeutics collaborated with Takeda, in a multi-target agreement for the discovery of breakthrough antibody therapies to potentially treat variety of gastrointestinal diseases, cancers and other disorders.

Jul 2018: Pluristem Therapeutics Inc was granted patent by the Japan Patent Office for the treatment of Acute Radiation Syndrome (ARS) and its impact on the gastrointestinal tract.

Major players: ABBOTT, ALLERGAN PLC, ASTELLAS PHARMA INC, ASTRAZENECA, BAYER AG, GLAXOSMITHKLINE PLC, JANSSEN PHARMACEUTICALS, INC (JOHNSON & JOHNSON), PFIZER INC, SALIX PHARMACEUTICALS, AND TAKEDA PHARMACEUTICAL COMPANY LIMITED, among others.

Reasons to Purchase the Gastrointestinal Therapeutics Market Report

Current and future of Gastrointestinal Therapeutics market outlook in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3-month analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Gastrointestinal Therapeutics Market Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Market Dynamics

  • 6.1 Drivers
    • 6.1.1 Rapid Lifestyle Changes Leading to Increased GI Diseases and Cancer Lesions
    • 6.1.2 Rising Surgical Treatments for GI Diseases
    • 6.1.3 Increasing Investments in R&D by Pharmaceutical Companies in Biologics and Biosimilars
  • 6.2 Restraints
    • 6.2.1 Rising Socio-Economic Burden Associated with Gastrointestinal Disorders
    • 6.2.2 Increasing Number of Patent Expirations
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Type
    • 7.1.1 Branded
    • 7.1.2 Generics
  • 7.2 By Dosage Form
    • 7.2.1 Oral
    • 7.2.2 Parenteral
    • 7.2.3 Others
  • 7.3 By Application
    • 7.3.1 Ulcerative Colitis
    • 7.3.2 Irritable Bowel Syndrome
    • 7.3.3 Crohn's Disease
    • 7.3.4 Celiac Disease
    • 7.3.5 Gastroenteritis
    • 7.3.6 Gastric Cancer
    • 7.3.7 Others
  • 7.4 By Geography
    • 7.4.1 North America
      • 7.4.1.1 US
      • 7.4.1.2 Canada
      • 7.4.1.3 Mexico
    • 7.4.2 Europe
      • 7.4.2.1 France
      • 7.4.2.2 Germany
      • 7.4.2.3 UK
      • 7.4.2.4 Italy
      • 7.4.2.5 Spain
      • 7.4.2.6 Rest of Europe
    • 7.4.3 Asia-Pacific
      • 7.4.3.1 China
      • 7.4.3.2 Japan
      • 7.4.3.3 India
      • 7.4.3.4 Australia
      • 7.4.3.5 South Korea
      • 7.4.3.6 Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • 7.4.4.1 GCC
      • 7.4.4.2 South Africa
      • 7.4.4.3 Rest of MEA
    • 7.4.5 South America
      • 7.4.5.1 Brazil
      • 7.4.5.2 Argentina
      • 7.4.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbott
  • 9.2 Allergan PLC
  • 9.3 Astellas Pharma Inc.
  • 9.4 AstraZeneca
  • 9.5 Bayer AG
  • 9.6 GlaxoSmithKline PLC
  • 9.7 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • 9.8 Pfizer Inc.
  • 9.9 Salix Pharmaceuticals
  • 9.10 Takeda Pharmaceutical Company Limited

List Not Exhaustive

10. Future of the Market

Back to Top